Organon & Co | OGN - Cash And Equivalent


Organon & Co reported $1.12B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Celltrion KRW 56.79B 6.92B Mar/2026
Cspc Pharmaceutical CNY 7.57B 793.73M Jun/2025
Deva Holding AS TRY 775.92M 574.67M Sep/2023
Dianthus Therapeutics USD 627.67M 576.58M Mar/2026
Divis Laboratories Ltd INR 4.15B 31.87B Mar/2025
Gilead Sciences USD 7.56B 234M Dec/2025
Glaxosmithkline GBP 3.44B 146M Mar/2026
Kangmei Pharma CNY 1.23B 48.16M Mar/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Laboratorios Farma EUR 46.11M 18.92M Jun/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Medical Developments International AUD 17.84M 219K Jun/2025
Merck USD 5.33B 9.24B Mar/2026
Neuren Pharmaceuticals AUD 5.91M 2.76M Jun/2025
Novartis USD 6.88B 2.68B Mar/2026
Organigram Holdings CAD 4.29M 3.28M Mar/2026
Organon & Co USD 1.12B 542M Mar/2026
Pharma Mar EUR 48.86M 31.05M Mar/2026
Qiagen NV USD 839M 516.58M Dec/2025
Sartorius EUR 573.8M 32.4M Mar/2026
Sino Biopharmaceutical CNY 3.38B 2.09B Dec/2024
Tilray USD 264.83M 43.16M Jun/2025
Zealand Pharma A/S 4.58B 1.4B Dec/2025